NICE backs Rozlytrek for subset of NSCLC patients
Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originates
Read More
Tag: ROS1
Roche launches first in vitro lung cancer diagnostic test
The biomarker is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market.
Read More
Roche to buy Ignyta for $1.7 billion
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Read More
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
